NeuroScientific Biopharmaceuticals Investor Relations Material
Latest events
M&A Announcement
30 Jun, 2025
Q3 2025 TU
23 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from NeuroScientific Biopharmaceuticals Limited
Access all reports
NeuroScientific Biopharmaceuticals Limited is a biotechnology company focused on researching and developing therapies for neurodegenerative diseases and neurotrauma. The company’s work centers on novel peptide-based treatments aimed at conditions such as Alzheimer’s disease, multiple sclerosis, and other neurological disorders that involve degeneration or damage to nerve cells. The company is headquartered in Perth, Australia, and its shares are listed on the ASX.
Key slides for NeuroScientific Biopharmaceuticals Limited
M&A Announcement
NeuroScientific Biopharmaceuticals Limited
M&A Announcement
NeuroScientific Biopharmaceuticals Limited
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
NSB
Country
🇦🇺 Australia